La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Medtronic Gestione
Gestione criteri di controllo 2/4
Medtronic's Il CEO è Geoff Martha, nominato in Apr2020, e ha un mandato di 4.33 anni. la retribuzione annua totale è $ 20.08M, composta da 6.7% di stipendio e 93.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.006% delle azioni della società, per un valore di $ 6.53M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.3 anni e 9.6 anni.
Informazioni chiave
Geoff Martha
Amministratore delegato
US$20.1m
Compenso totale
| Percentuale dello stipendio del CEO | 6.7% |
| Mandato del CEO | 4.3yrs |
| Proprietà del CEO | 0.006% |
| Durata media del management | 3.3yrs |
| Durata media del Consiglio di amministrazione | 9.6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Medtronic: Still A Buy Before Earnings
Aug 17Returns At Medtronic (NYSE:MDT) Appear To Be Weighed Down
Aug 08
Medtronic: An Out Of Favor Healthcare Stock With A Pulse On Profit Potential
Jul 16At US$77.06, Is Medtronic plc (NYSE:MDT) Worth Looking At Closely?
Jul 11Medtronic (NYSE:MDT) Is Paying Out A Larger Dividend Than Last Year
Jun 27Medtronic: Why I Disagree With The Crowd
Jun 14Medtronic's (NYSE:MDT) Upcoming Dividend Will Be Larger Than Last Year's
Jun 10Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued
May 27Medtronic (NYSE:MDT) Has Announced That It Will Be Increasing Its Dividend To $0.70
May 26These 4 Measures Indicate That Medtronic (NYSE:MDT) Is Using Debt Reasonably Well
May 22Medtronic Stock Looks Promising Before Fiscal Q4 2024 Release
May 13Is Medtronic plc (NYSE:MDT) Trading At A 20% Discount?
May 0135% Undervalued? Medtronic's Future Looks Very Bright
Apr 12Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now
Mar 27Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth
Mar 11Medtronic (NYSE:MDT) Has Announced A Dividend Of $0.69
Mar 11Medtronic: Its Recent Beat Proves That It Continues To Be A Rock
Feb 25Results: Medtronic plc Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 22Medtronic: A Good Choice For Dividend Investors Seeking For Low Volatility
Feb 16A Look At The Fair Value Of Medtronic plc (NYSE:MDT)
Jan 31Does Medtronic (NYSE:MDT) Have A Healthy Balance Sheet?
Jan 16Medtronic Stock's Rally Is Set To Continue
Jan 11Medtronic plc's (NYSE:MDT) Price Is Out Of Tune With Earnings
Dec 29Medtronic's (NYSE:MDT) Dividend Will Be $0.69
Dec 12Medtronic: The GLP-1 Drug Headwinds Are Overblown
Dec 103.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic
Nov 28Returns On Capital At Medtronic (NYSE:MDT) Have Hit The Brakes
Nov 19Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings
Nov 17Medtronic Faces Potential Decline Despite Financial Strength
Oct 29An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 21% Undervalued
Oct 19Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Oct 04Medtronic: Improved Guidance, Historically Cheap P/E, Yield Reaches 3.5%
Sep 27Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69
Sep 18Medtronic: The Tide Is Turning
Aug 24Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69
Aug 21Medtronic: Dark Clouds Are Clearing - Outperformance Ahead
Aug 14Return Trends At Medtronic (NYSE:MDT) Aren't Appealing
Aug 11Medtronic: Expanding Product Portfolio Without Affecting Dividend Growth
Jul 15Are Medtronic plc (NYSE:MDT) Investors Paying Above The Intrinsic Value?
Jul 09Is Medtronic (NYSE:MDT) A Risky Investment?
Jun 21Medtronic: Weak Forecasts Spoiled Strong Results For The Reporting Quarter
Jun 21Is Medtronic's Dividend In A Good Place?
Jun 14Medtronic (NYSE:MDT) Is Increasing Its Dividend To $0.69
Jun 03Medtronic: Solid Q4 Earnings, Don't Fret About Guidance
May 26Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Apr 26 2024 | US$20m | US$1m | US$4b |
| Jan 26 2024 | n/a | n/a | US$4b |
| Oct 27 2023 | n/a | n/a | US$4b |
| Jul 28 2023 | n/a | n/a | US$4b |
| Apr 28 2023 | US$15m | US$1m | US$4b |
| Jan 27 2023 | n/a | n/a | US$4b |
| Oct 28 2022 | n/a | n/a | US$4b |
| Jul 29 2022 | n/a | n/a | US$5b |
| Apr 29 2022 | n/a | n/a | US$5b |
| Jan 28 2022 | n/a | n/a | US$5b |
| Oct 29 2021 | n/a | n/a | US$5b |
| Jul 30 2021 | n/a | n/a | US$4b |
| Apr 30 2021 | US$18m | US$1m | US$4b |
| Jan 29 2021 | n/a | n/a | US$3b |
| Oct 30 2020 | n/a | n/a | US$4b |
| Jul 31 2020 | n/a | n/a | US$4b |
| Apr 24 2020 | US$6m | US$905k | US$5b |
| Jan 24 2020 | n/a | n/a | US$5b |
| Oct 25 2019 | n/a | n/a | US$5b |
| Jul 26 2019 | n/a | n/a | US$4b |
| Apr 26 2019 | US$4m | US$693k | US$5b |
Compensazione vs Mercato: La retribuzione totale di Geoff ($USD 20.08M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 13.21M ).
Compensazione vs guadagni: La retribuzione di Geoff è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Geoff Martha (54 yo)
4.3yrs
Mandato
US$20,084,630
Compensazione
Mr. Geoffrey Straub Martha, also known as Geoff, serves as Director at Medtronic plc since November 01, 2019 and serves as its Chief Executive Officer since April 27, 2020. He serves as Director of NextEra...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.3yrs | US$20.08m | 0.0060% $ 6.5m | |
| Executive VP & President of Cardiovascular Portfolio | no data | US$6.55m | 0.0021% $ 2.3m | |
| Executive VP & President of Neuroscience Portfolio | 4.8yrs | US$6.44m | 0.00092% $ 998.3k | |
| Executive Vice President of Global Operations & Supply Chain | 3.3yrs | US$7.66m | 0.0015% $ 1.6m | |
| Senior Vice President of Global Financial Planning and Analysis & Interim CFO | no data | Nessun dato | 0.00045% $ 488.3k | |
| Senior Vice President of Global Operations and Business Services | 7.8yrs | Nessun dato | Nessun dato | |
| Senior VP | 3.2yrs | Nessun dato | 0.0022% $ 2.4m | |
| Senior VP and Chief Technology & Innovation Officer | 1.2yrs | Nessun dato | Nessun dato | |
| Senior VP and Chief Scientific & Medical Officer | 2.3yrs | Nessun dato | Nessun dato | |
| VP & Head of Investor Relations | 9.2yrs | Nessun dato | Nessun dato | |
| Executive VP | 2.5yrs | US$11.72m | 0.0019% $ 2.1m | |
| Senior VP & Chief Communications Officer | 3.6yrs | Nessun dato | Nessun dato |
3.3yrs
Durata media
59yo
Età media
Gestione esperta: Il team dirigenziale di MDT è considerato esperto (durata media dell'incarico 3.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.8yrs | US$20.08m | 0.0060% $ 6.5m | |
| Independent Director | 11.6yrs | US$365.06k | 0.0012% $ 1.3m | |
| Independent Director | 17.6yrs | US$350.06k | 0.0015% $ 1.6m | |
| Independent Director | 9.6yrs | US$385.06k | 0.0034% $ 3.6m | |
| Lead Independent Director | 9.6yrs | US$410.06k | 0.0028% $ 3.1m | |
| Independent Director | 24.6yrs | US$375.06k | 0.0031% $ 3.3m | |
| Independent Director | 5.4yrs | US$370.06k | 0.00048% $ 520.8k | |
| Independent Director | 10.6yrs | US$370.06k | 0.0010% $ 1.1m | |
| Independent Director | 2.2yrs | US$350.06k | 0.00012% $ 130.2k | |
| Independent Director | 3.9yrs | US$370.06k | 0.00032% $ 347.2k | |
| Independent Director | 1.2yrs | US$306.97k | 0% $ 0 |
9.6yrs
Durata media
64yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MDT sono considerati esperti (durata media dell'incarico 9.6 anni).